Zevra Therapeutics, Inc.
ZVRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.7% | 26.9% | 69.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94% | 52.2% | 93.4% | 88.7% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 5.6% | 311.3% | 8.3% | -137.2% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -5.4% | 288.7% | -15.2% | -296.8% |
| EPS Diluted | -0.01 | 1.364 | -0.057 | -0.67 |
| % Growth | -100.7% | 2,479.9% | 91.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |